Literature DB >> 26369977

VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection.

Teclegiorgis Gebremariam1, Nathan P Wiederhold2, Annette W Fothergill2, Edward P Garvey3, William J Hoekstra3, Robert J Schotzinger3, Thomas F Patterson4, Scott G Filler5, Ashraf S Ibrahim6.   

Abstract

We studied the efficacy of the investigational drug VT-1161 against mucormycosis. VT-1161 had more potent in vitro activity against Rhizopus arrhizus var. arrhizus than against R. arrhizus var. delemar. VT-1161 treatment demonstrated dose-dependent plasma drug levels with prolonged survival time and lowered tissue fungal burden in immunosuppressed mice infected with R. arrhizus var. arrhizus and was as effective as high-dose liposomal amphotericin B treatment. These results support further development of VT-1161 against mucormycosis.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26369977      PMCID： PMC4649228          DOI： 10.1128/AAC.01437-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

Authors:  Kieren A Marr; Rachel A Carter; Fulvio Crippa; Anna Wald; Lawrence Corey
Journal:  Clin Infect Dis       Date:  2002-02-26       Impact factor: 9.079

2.  Zygomycosis: reemergence of an old pathogen.

Authors:  Carol A Kauffman
Journal:  Clin Infect Dis       Date:  2004-07-30       Impact factor: 9.079

3.  Design and optimization of highly-selective fungal CYP51 inhibitors.

Authors:  William J Hoekstra; Edward P Garvey; William R Moore; Stephen W Rafferty; Christopher M Yates; Robert J Schotzinger
Journal:  Bioorg Med Chem Lett       Date:  2014-06-09       Impact factor: 2.823

4.  Zygomycosis in the 1990s in a tertiary-care cancer center.

Authors:  D P Kontoyiannis; V C Wessel; G P Bodey; K V Rolston
Journal:  Clin Infect Dis       Date:  2000-06-13       Impact factor: 9.079

Review 5.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

Review 6.  Improved outcome of zygomycosis in patients with hematological diseases?

Authors:  B Gleissner; A Schilling; I Anagnostopolous; I Siehl; E Thiel
Journal:  Leuk Lymphoma       Date:  2004-07

7.  Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi.

Authors:  Shahid Husain; Barbara D Alexander; Patricia Munoz; Robin K Avery; Sally Houston; Timothy Pruett; Richard Jacobs; Edward A Dominguez; Jan G Tollemar; Katherine Baumgarten; Chen M Yu; Marilyn M Wagener; Peter Linden; Shimon Kusne; Nina Singh
Journal:  Clin Infect Dis       Date:  2003-07-09       Impact factor: 9.079

8.  Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae.

Authors:  Ashraf S Ibrahim; Valentina Avanessian; Brad Spellberg; John E Edwards
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011.

Authors:  Robyn Neblett Fanfair; Kaitlin Benedict; John Bos; Sarah D Bennett; Yi-Chun Lo; Tolu Adebanjo; Kizee Etienne; Eszter Deak; Gordana Derado; Wun-Ju Shieh; Clifton Drew; Sherif Zaki; David Sugerman; Lalitha Gade; Elizabeth H Thompson; Deanna A Sutton; David M Engelthaler; James M Schupp; Mary E Brandt; Julie R Harris; Shawn R Lockhart; George Turabelidze; Benjamin J Park
Journal:  N Engl J Med       Date:  2012-12-06       Impact factor: 91.245

10.  The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme.

Authors:  A G S Warrilow; C M Hull; J E Parker; E P Garvey; W J Hoekstra; W R Moore; R J Schotzinger; D E Kelly; S L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191
View more
  15 in total

1.  Azole Resistance Reduces Susceptibility to the Tetrazole Antifungal VT-1161.

Authors:  Brian C Monk; Mikhail V Keniya; Manya Sabherwal; Rajni K Wilson; Danyon O Graham; Harith F Hassan; Danni Chen; Joel D A Tyndall
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

Review 2.  The antifungal pipeline: a reality check.

Authors:  John R Perfect
Journal:  Nat Rev Drug Discov       Date:  2017-05-12       Impact factor: 84.694

3.  PCR-Based Approach Targeting Mucorales-Specific Gene Family for Diagnosis of Mucormycosis.

Authors:  Clara Baldin; Sameh S M Soliman; Heewon H Jeon; Sondus Alkhazraji; Teclegiorgis Gebremariam; Yiyou Gu; Vincent M Bruno; Oliver A Cornely; Helen L Leather; Michele W Sugrue; John R Wingard; David A Stevens; John E Edwards; Ashraf S Ibrahim
Journal:  J Clin Microbiol       Date:  2018-09-25       Impact factor: 5.948

Review 4.  Drugs in Clinical Development for Fungal Infections.

Authors:  Maria F Gonzalez-Lara; Jose Sifuentes-Osornio; Luis Ostrosky-Zeichner
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

Review 5.  Challenges in the diagnosis and treatment of mucormycosis.

Authors:  A Skiada; C Lass-Floerl; N Klimko; A Ibrahim; E Roilides; G Petrikkos
Journal:  Med Mycol       Date:  2018-04-01       Impact factor: 4.076

6.  Prophylactic Treatment with VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection.

Authors:  Teclegiorgis Gebremariam; Sondus Alkhazraji; Lin Lin; Nathan P Wiederhold; Edward P Garvey; William J Hoekstra; Robert J Schotzinger; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 7.  Current Treatment Options for COVID-19 Associated Mucormycosis: Present Status and Future Perspectives.

Authors:  Yasasve Madhavan; Kadambari Vijay Sai; Dilip Kumar Shanmugam; Aashabharathi Manimaran; Karthigadevi Guruviah; Yugal Kishore Mohanta; Divyambika Catakapatri Venugopal; Tapan Kumar Mohanta; Nanaocha Sharma; Saravanan Muthupandian
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

8.  VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans.

Authors:  Timothy J Break; Jigar V Desai; Mukil Natarajan; Elise M N Ferre; Christina Henderson; Adrian M Zelazny; Ulrich Siebenlist; William J Hoekstra; Robert J Schotzinger; Edward P Garvey; Michail S Lionakis
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

Review 9.  Therapy of Mucormycosis.

Authors:  Nikolaos V Sipsas; Maria N Gamaletsou; Amalia Anastasopoulou; Dimitrios P Kontoyiannis
Journal:  J Fungi (Basel)       Date:  2018-07-31

Review 10.  Investigational Agents for the Treatment of Resistant Yeasts and Molds.

Authors:  Garret T Seiler; Luis Ostrosky-Zeichner
Journal:  Curr Fungal Infect Rep       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.